Promising results for new deCODE heart drug

The biopharmaceutical company deCODE Genetics Inc has described a recent trial for a drug to prevent heart attacks as having positive results, according to

The Iceland-based firm conducted a mid-stage trial of DG051, a drug developed in the fight against heart attacks. Results of the study demonstrated that the drug considerably decreased the production of a molecule that is supposed to increase the risk of heart attack. The subjects were patients with a history of coronary artery disease or heart attack, and who were also taking additional accompanying medications.

Since there were no adverse results in the study, the second part of the mid-stage study plans to recruit 400 patients to begin in the spring.